This year has turned against biotech investors, as the
long-awaited correction came on hard in March and April. While
conditions seem to have stabilized for the time being, Biogen Idec (NASDAQ: BIIB )
remains an outperformer as investors have slower to dump shares of
more established biotechs with strong launch and pipeline stories like
Biogen, Gilead, and Regeneron.
Biogen's pipeline is has higher risk than many of its peers, but the
rewards if SMNrx, STX-100, or the anti-LINGO antibody BIIB 033 work out
will be considerable and Biogen has lower risk drivers like the ongoing
Tecfidera launch and rollout of new hemophilia compounds to keep
investors engaged.
Read more here:
Is Biogen Idec Inc a Buy?
No comments:
Post a Comment